Literature DB >> 12014972

Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials.

Pál Herczegh1, Thomas B Buxton, James C McPherson, Arpád Kovács-Kulyassa, Phyllis D Brewer, Ferenc Sztaricskai, Gary G Stroebel, Kent M Plowman, Dan Farcasiu, John F Hartmann.   

Abstract

Bisphosphonates conjugated to fluoroquinolone antibacterials through an intermediate carbon had better activity than conjugates lacking the carbon. Virtually all molar-based activity of these esterified bisphosphonate derivatives was identical to that of its parent. De-esterified free-acid forms retained good activity against most Gram-negative bacteria, but not against Gram-positives. A free-acid derivative remained bound to washed bone and completely inhibited Staphylococcus aureus growth. The more potent parent, ciprofloxacin, failed to bind significantly, and bacterial growth occurred.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014972     DOI: 10.1021/jm0105326

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.

Authors:  Jivan N Yewle; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2011-12-05       Impact factor: 4.774

2.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

3.  Measurement of Ototoxicity Following Intracochlear Bisphosphonate Delivery.

Authors:  Woo Seok Kang; Kim Nguyen; Charles E McKenna; William F Sewell; Michael J McKenna; David H Jung
Journal:  Otol Neurotol       Date:  2016-07       Impact factor: 2.311

4.  Bis-enoxacin inhibits bone resorption and orthodontic tooth movement.

Authors:  E J Toro; J Zuo; A Gutierrez; A Guiterrez; R L La Rosa; A J Gawron; V Bradaschia-Correa; V Arana-Chavez; C Dolce; M F Rivera; L Kesavalu; I Bhattacharyya; J K Neubert; L S Holliday
Journal:  J Dent Res       Date:  2013-08-19       Impact factor: 6.116

5.  Radical reaction of sodium hypophosphite with terminal alkynes: synthesis of 1,1-bis-H-phosphinates.

Authors:  Sonia Gouault-Bironneau; Sylvine Deprèle; Amber Sutor; Jean-Luc Montchamp
Journal:  Org Lett       Date:  2005-12-22       Impact factor: 6.005

6.  Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms.

Authors:  Parish P Sedghizadeh; Shuting Sun; Adam F Junka; Eric Richard; Keivan Sadrerafi; Susan Mahabady; Neema Bakhshalian; Natalia Tjokro; Marzenna Bartoszewicz; Monika Oleksy; Patrycja Szymczyk; Mark W Lundy; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino
Journal:  J Med Chem       Date:  2017-02-13       Impact factor: 7.446

Review 7.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted antiresorptives.

Authors:  Sehkar Oktay; Sasanka S Chukkapalli; Mercedes F Rivera-Kweh; Irina M Velsko; L Shannon Holliday; Lakshmyya Kesavalu
Journal:  J Periodontol       Date:  2015-01       Impact factor: 6.993

Review 9.  Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview.

Authors:  Sujit Arun Desai; Arehalli Manjappa; Preeti Khulbe
Journal:  J Egypt Natl Canc Inst       Date:  2021-02-08

Review 10.  Bisphosphonates for delivering drugs to bone.

Authors:  Shuting Sun; Jianguo Tao; Parish P Sedghizadeh; Philip Cherian; Adam F Junka; Esmat Sodagar; Lianping Xing; Robert K Boeckman; Venkatesan Srinivasan; Zhenqiang Yao; Brendan F Boyce; Brea Lipe; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino
Journal:  Br J Pharmacol       Date:  2021-04-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.